CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Hwi Seung Kim, Woo Je Lee
Diabetes Metab J. 2022;46(4):665-666.   Published online July 27, 2022
DOI: https://doi.org/10.4093/dmj.2022.0166

Excel Download

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes & Metabolism Journal. 2022;46(4):663-664   Crossref logo
Link1 Link2 Link3

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Diabetes & Metabolism Journal. 2022;46(4):665-666   Crossref logo
Link1 Link2 Link3

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes & Metabolism Journal. 2022;46(4):658-662   Crossref logo
Link1 Link2 Link3

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
Canadian Journal of Diabetes. 2021;45(3):291-302   Crossref logo
Link1 Link2

1477-PUB: The Comparison between Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist Treatment Depending on the Change in Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus on the Renal Function
Diabetes. 2022;71(Supplement_1):   Crossref logo
Link1 Link2

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
Journal of Diabetes Investigation. 2019;10(6):1518-1526   Crossref logo
Link1 Link2 Link3

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
Frontiers in Endocrinology. 2020;11:   Crossref logo
Link1

Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting
Diabetes Research and Clinical Practice. 2021;180:109035   Crossref logo
Link1 Link2

Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study
Canadian Journal of Diabetes. 2019;43(3):186-192   Crossref logo
Link1 Link2

The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
European Heart Journal Supplements. 2020;22(Supplement_L):L28-L32   Crossref logo
Link1 Link2